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OBJECTIVES: On May 2010 Greece reached an agreement with a joint team of the
International Monetary Fund, the European Commission and the European Central
Bank, as the country faced severe fiscal problems. According to the Agreement,
public pharmaceutical expenditure should be reduced from 1.9% to 1% of GDP,
while the reduction on health services and social security expenditure should be
accounted for 1.5 billion euros and 1.2 respectively. The aim of the study was to
evaluate the progress of the measures taken and to estimate their impact on health
expenditure and provision of services.METHODS: For the purpose of the study, we
used data from the Stand-By Arrangement and its reviews, Hellenic Statistical
Authority and Greek System of National Accounts, as well as published data in the
literature. RESULTS: The cuts of wages in public and private sector (15%) and the
increase of unemployment (from 9% to 15%) resulted in increased demand for
public hospital care by 24% as a consequence of reduced demand (30%) in hospital
units of private sector, while a decrease in demand for primary health care in both
public and private sector by 10% and 35% respectively was observed. In addition,
the cost of time in public hospitals is steadily increased, due to surgical interven-
tions and the use of high technology services, as well as because of reductions on
hospital budgets for medical equipment procurements. CONCLUSIONS: Although
the impact of the implemented reforms and policies in private health expenditures
is already visible the significant reduction of health services inputs causes a de-
crease in quantity and quality of services. The need for balanced development
relating both to supply and demand side requires structural reforms in healthcare
sector as well as transition from a costly technological model to a health system
based on primary care and public health.
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IN SEARCH OF REFORM FOR THE GREEK HEALTH CARE SYSTEM: DEPICTING
THE KEY OPINION LEADERS’ VIEWS
Tsiantou V, Athanasakis K, Pavi E, Kyriopoulos J
National School of Public Health, Athens, Greece
OBJECTIVES: Financial crisis in Greece raised the need for more efficient use of
resources in the health care sector. A number of policies have been proposed for
this purpose. The aim of this study was to investigate the views of healthcare Key
Opinion Leaders (KOLs) on the proposed interventions. METHODS: Seventy-two
KOLs were invited to participate in an expert panel survey. For the purpose of the
study a closed questionnaire was developed comprising of six sections based on
the proposed policies i.e. audit, economic evaluation, financial management, pric-
ing, health care funding and procurement system. During the meeting KOLs were
asked to select the answers that best represented their views on the appropriate-
ness/feasibility of each policy under study and express their opinion in an open
discussion that followed. RESULTS: Forty experts (55.5%) accepted the invitation.
The majority of participants argued that audit is necessary in the health sector but
half of them believed that at present it is not feasible. They thought that a certified
public institution should be responsible for the audit process. The indicators and
targets should be set nationally but can be differentiated locally. Very important
was the finding that the audit report should be a criterion for each institution’s
(hospital) funding and if results are negative then a penalty should be applied.
Implementation of economic evaluation in decision-making was considered ex-
tremely important. A reform in the hospital’s financing was reported as necessary
and the most suitable reimbursement technique is a combination of global budget
and DRG system. Physicians should be reimbursed based on qualitative criteria.
Finally, procurement system should and can be reformed immediately according
to the expert panel. CONCLUSIONS: All proposed interventions were evaluated
positively but experts considered that there is a greater need for an audit mecha-
nism and reform of the procurement system to be implemented first.
Health Care Use & Policy Studies – Risk Sharing/Performance-Based Agreements
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LANDMARK CER STUDY METHODS REVIEW
Cummins G, Britton K, Doyle J
Quintiles, Hawthorne, NY, USA
OBJECTIVES: Comparative effectiveness research (CER), constitutes a ‘real-world’
comparison of the risk-benefit profile of a new product with the existing standard
of care. In the US, the federal government is supporting the expansion of CER
through funding made available in the American Recovery and Reinvestment Act
of 2009 (ARRA) and by establishing the Patient-Centered Outcomes Research Insti-
tute through the Patient Protection and Affordable Care Act of 2010. Similarly in
Europe there is push for relative effectiveness studies. Industry and governments
have deployed a variety of experimental research design methods to appraise real-
world performance of products vis-à-vis competitors. An evaluation of five recent
studies was analyzed to assess CER implications. METHODS: We performed a
structured review and assessment of five different therapeutic classes (antihyper-
lipidemics, antipsychotics, antiplatelets, anti-VEGF, and insulin analogues) inves-
tigated in CER related studies (AIM-HIGH, CATIE, GeCCO, CATT, and AHRQ CER
Premixed Insulin Analogues). CER metrics included study population including
comparative agent(s), relevance of conclusions and interpretations outside the
study population. RESULTS: Study designs varied including head to head, study
agent versus placebo, and systematic literature reviews as well as various types of
metrics (safety, efficacy, and effectiveness). One study was stopped early due to
lack of benefit, three studies determine equivalence of effectiveness (cost, clinical).
Another study is still underway (GeCCO) with results expected towards the end of
2011. CONCLUSIONS: The number of CER focused studies is increasing with wide
variability in study designs, comparators, populations, and endpoints. With the
surge of new agencies dedicated to this evolving field of research (e.g., PCORI in the
US), it will be important to evaluate the various types of CER studies and resulting
information from a multi-stakeholder perspective.
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MULTI-STAKEHOLDER SURVEY OF COMPARATIVE EFFECTIVENESS RESEARCH
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OBJECTIVES: Comparative effectiveness research (CER) is designed to inform
health care decision making through evidence generation on relative benefit for
treatment options to multiple stakeholders. Payors have experience utilizing self-
generated CER information to inform policy decisions including: formulary tier
placement, prior authorization requirements, other utilization control techniques,
and cost control mechanisms. However, wide acceptance and regular use of CER
has yet to be fully realized. The Quintiles New Health Report 2011 survey assessed
how and to the extent national payors were receptive to the implementation of
CER. METHODS: The New Health Report 2011, designed by Quintiles, surveyed
multiple stakeholders to better understand each stakeholder’s perceptions toward
health care, focusing on perceived value. More than 200 biopharmaceutical exec-
utives, 153 managed care executives, 500 physicians, and 30 MCOs were sampled in
the survey. The focus was payor perspective in relation to value and CER. RESULTS:
Though the vast majority of payors valued CER and vocalized their desire for more
CER data, fewer than half of payors actively promoted CER on their websites or in
published literature. Some payors do advocate and sometimes require CER data
from manufacturers, 85% of surveyed payors utilized self-generated CER data
rather than data provided by manufacturers. Biopharmaceutical executives were
overwhelming in agreement to invest more in long-term outcomes data, but only
44% had even access readily available outcomes data to demonstrate value, while
38% admitted that they did not have any access at all to CER information.
CONCLUSIONS: A large percentage of payors recognize the short/long term value
and utility of CER data, but are not accessing the available data and/or are not sure
how to access the data. To encourage greater utilization of CER, stakeholders must
be more assertive in capturing and evaluating CER information, while partnering
together to create more transparent and standardized CER guidelines.
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THE BURDEN OF EVIDENCE IN THE PHARMACEUTICAL APPRAISAL PROCESS
Brooks-Rooney C, Costello S, Timm B, Leonard SA, Hamer N
Costello Medical Consulting, Cambridge, UK
OBJECTIVES: The emergence of evidence-based medicine (EBM) in the past decade
has raised the level of the scientific data required during the drug appraisal pro-
cess. It is no longer sufficient to prove that a new treatment is better than placebo
in one clinical trial; healthcare decision makers additionally require information
on how it performs in multiple trials, including against other treatments in the
disease area. Systematic reviews, meta-analyses, comparative effectiveness stud-
ies and head-to-head trials are becoming essential in the appraisal process as
decision makers demand higher levels of evidence from manufacturers. This anal-
ysis reviewed PubMed articles for trends in the numbers of such studies from
2001-2010. METHODS: The titles of PubMed articles were searched for “systematic
review”, “meta-analysis”, “comparative effectiveness” and “head-to-head” along
with the year of publication. RESULTS: The mean annual change in the number of
articles indexed by PubMed over the period was 6.0%, which represents the back-
ground increase in the body of scientific evidence. In contrast, the mean annual
change for systematic reviews was 27.4% (from 388 in 2001, to 3406 in 2010), 23.2%
for meta-analyses (462 to 2,996), 80.5% for comparative effectiveness studies (5 to
247) and 23.1% for head-to-head trials (11 to 53). These increases are all substan-
tially higher than the background increase in PubMed articles. The increase in
comparative effectiveness studies in particular illustrates the strength of interest
in this area of research. CONCLUSIONS: EBM is now accepted globally as the pre-
ferred method of appraising new treatments; as the pharmaceutical industry
adapts to this landscape, the number of studies examining the evidence base has
increased considerably in the past decade. The next movement in the industry has
already arrived, that of direct comparative effectiveness, and whilst the number of
head to head studies has already increased we can expect to see further increases
over the next decade.
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OBJECTIVES: To identify and characterize publicly available cases and related
trends for performance-based schemes. METHODS: We performed a systematic
review of performance-based schemes over the past 15 years (1996 – 2011) using
publicly available databases and reports from colleagues and health care experts.
These were categorized according to a previously published taxonomy of scheme
types and assessed in terms of the underlying product and market attributes for
each scheme. Macro-level trends were identified related to the timing of scheme
adoption, countries involved, types of schemes, and product and market factors.
RESULTS:Our search yielded in excess of 110 schemes. From this set, we identified:
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